Who are the key players in the neurofibromatosis type 1 market?

Some of the key players are Astrazeneca plc, Merck, Others.

Global Neurofibromatosis Type 1 Market Insights and Forecast to 2028

Code: QYRE-Auto-23X8187

Report

January 2022

76 Pages

QYResearch

Region: Global,

Description

Table of Content

Tables & Figures

FEATURED COMPANIES

Astrazeneca plc

Merck

NF1 is a debilitating genetic condition that affects one in every 3,000 to 4,000 individuals. It is caused by a spontaneous or inherited mutation in the NF1 gene and is associated with many symptoms, including soft lumps on and under the skin (cutaneous neurofibromas) and skin pigmentation (so-called ‘café au lait’ spots) and, in 30-50% of patients, tumours develop on the nerve sheaths (plexiform neurofibromas).

Market Analysis and Insights: Global Neurofibromatosis Type 1 Market

Due to the COVID-19 pandemic, the global Neurofibromatosis Type 1 market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period.

Fully considering the economic change by this health crisis, 10 mg accounting for % of the Neurofibromatosis Type 1 global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period.

While Hospitals segment is altered to an % CAGR throughout this forecast period.

China Neurofibromatosis Type 1 market size is valued at US$ million in 2021, while the US and Europe Neurofibromatosis Type 1 are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period.

As for the Europe Neurofibromatosis Type 1 landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.

The global key manufacturers of Neurofibromatosis Type 1 include AstraZeneca and Merck etc. In 2021, the global top five players have a share approximately % in terms of revenue.

Global Neurofibromatosis Type 1 Scope and Segment

Neurofibromatosis Type 1 market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Neurofibromatosis Type 1 market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.

Segment by Type

10 mg

25 mg

Segment by Application

Hospitals

Clinics

Others

BY COMPANY

AstraZeneca

Merck

BY REGION

North America

U.S.

Canada

Europe

Germany

France

U.K.

Italy

Russia

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Indonesia

Thailand

Malaysia

Philippines

Vietnam

Latin America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

FEATURED COMPANIES

Astrazeneca plc

Merck

1 Study Coverage

1.1 Neurofibromatosis Type 1 Product Introduction

1.2 Market by Type

1.2.1 Global Neurofibromatosis Type 1 Market Size Growth Rate by Type, 2017 VS 2021 VS 2028

1.2.2 10 mg

1.2.3 25 mg

1.3 Market by Application

1.3.1 Global Neurofibromatosis Type 1 Market Size Growth Rate by Application, 2017 VS 2021 VS 2028

1.3.2 Hospitals

1.3.3 Clinics

1.3.4 Others

1.4 Study Objectives

1.5 Years Considered

2 Executive Summary

2.1 Global Neurofibromatosis Type 1 Sales Estimates and Forecasts 2017-2028

2.2 Global Neurofibromatosis Type 1 Revenue Estimates and Forecasts 2017-2028

2.3 Global Neurofibromatosis Type 1 Revenue by Region: 2017 VS 2021 VS 2028

2.4 Global Neurofibromatosis Type 1 Sales by Region

2.4.1 Global Neurofibromatosis Type 1 Sales by Region (2017-2022)

2.4.2 Global Sales Neurofibromatosis Type 1 by Region (2023-2028)

2.5 Global Neurofibromatosis Type 1 Revenue by Region

2.5.1 Global Neurofibromatosis Type 1 Revenue by Region (2017-2022)

2.5.2 Global Neurofibromatosis Type 1 Revenue by Region (2023-2028)

2.6 North America

2.7 Europe

2.8 Asia-Pacific

2.9 Latin America

2.10 Middle East & Africa

3 Competition by Manufacturers

3.1 Global Neurofibromatosis Type 1 Sales by Manufacturers

3.1.1 Global Top Neurofibromatosis Type 1 Manufacturers by Sales (2017-2022)

3.1.2 Global Neurofibromatosis Type 1 Sales Market Share by Manufacturers (2017-2022)

3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Neurofibromatosis Type 1 in 2021

3.2 Global Neurofibromatosis Type 1 Revenue by Manufacturers

3.2.1 Global Neurofibromatosis Type 1 Revenue by Manufacturers (2017-2022)

3.2.2 Global Neurofibromatosis Type 1 Revenue Market Share by Manufacturers (2017-2022)

3.2.3 Global Top 10 and Top 5 Companies by Neurofibromatosis Type 1 Revenue in 2021

3.3 Global Neurofibromatosis Type 1 Sales Price by Manufacturers (2017-2022)

3.4 Analysis of Competitive Landscape

3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Neurofibromatosis Type 1 Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.4.3 Global Neurofibromatosis Type 1 Manufacturers Geographical Distribution

3.5 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type

4.1 Global Neurofibromatosis Type 1 Sales by Type

4.1.1 Global Neurofibromatosis Type 1 Historical Sales by Type (2017-2022)

4.1.2 Global Neurofibromatosis Type 1 Forecasted Sales by Type (2023-2028)

4.1.3 Global Neurofibromatosis Type 1 Sales Market Share by Type (2017-2028)

4.2 Global Neurofibromatosis Type 1 Revenue by Type

4.2.1 Global Neurofibromatosis Type 1 Historical Revenue by Type (2017-2022)

4.2.2 Global Neurofibromatosis Type 1 Forecasted Revenue by Type (2023-2028)

4.2.3 Global Neurofibromatosis Type 1 Revenue Market Share by Type (2017-2028)

4.3 Global Neurofibromatosis Type 1 Price by Type

4.3.1 Global Neurofibromatosis Type 1 Price by Type (2017-2022)

4.3.2 Global Neurofibromatosis Type 1 Price Forecast by Type (2023-2028)

5 Market Size by Application

5.1 Global Neurofibromatosis Type 1 Sales by Application

5.1.1 Global Neurofibromatosis Type 1 Historical Sales by Application (2017-2022)

5.1.2 Global Neurofibromatosis Type 1 Forecasted Sales by Application (2023-2028)

5.1.3 Global Neurofibromatosis Type 1 Sales Market Share by Application (2017-2028)

5.2 Global Neurofibromatosis Type 1 Revenue by Application

5.2.1 Global Neurofibromatosis Type 1 Historical Revenue by Application (2017-2022)

5.2.2 Global Neurofibromatosis Type 1 Forecasted Revenue by Application (2023-2028)

5.2.3 Global Neurofibromatosis Type 1 Revenue Market Share by Application (2017-2028)

5.3 Global Neurofibromatosis Type 1 Price by Application

5.3.1 Global Neurofibromatosis Type 1 Price by Application (2017-2022)

5.3.2 Global Neurofibromatosis Type 1 Price Forecast by Application (2023-2028)

6 North America

6.1 North America Neurofibromatosis Type 1 Market Size by Type

6.1.1 North America Neurofibromatosis Type 1 Sales by Type (2017-2028)

6.1.2 North America Neurofibromatosis Type 1 Revenue by Type (2017-2028)

6.2 North America Neurofibromatosis Type 1 Market Size by Application

6.2.1 North America Neurofibromatosis Type 1 Sales by Application (2017-2028)

6.2.2 North America Neurofibromatosis Type 1 Revenue by Application (2017-2028)

6.3 North America Neurofibromatosis Type 1 Market Size by Country

6.3.1 North America Neurofibromatosis Type 1 Sales by Country (2017-2028)

6.3.2 North America Neurofibromatosis Type 1 Revenue by Country (2017-2028)

6.3.3 U.S.

6.3.4 Canada

7 Europe

7.1 Europe Neurofibromatosis Type 1 Market Size by Type

7.1.1 Europe Neurofibromatosis Type 1 Sales by Type (2017-2028)

7.1.2 Europe Neurofibromatosis Type 1 Revenue by Type (2017-2028)

7.2 Europe Neurofibromatosis Type 1 Market Size by Application

7.2.1 Europe Neurofibromatosis Type 1 Sales by Application (2017-2028)

7.2.2 Europe Neurofibromatosis Type 1 Revenue by Application (2017-2028)

7.3 Europe Neurofibromatosis Type 1 Market Size by Country

7.3.1 Europe Neurofibromatosis Type 1 Sales by Country (2017-2028)

7.3.2 Europe Neurofibromatosis Type 1 Revenue by Country (2017-2028)

7.3.3 Germany

7.3.4 France

7.3.5 U.K.

7.3.6 Italy

7.3.7 Russia

8 Asia Pacific

8.1 Asia Pacific Neurofibromatosis Type 1 Market Size by Type

8.1.1 Asia Pacific Neurofibromatosis Type 1 Sales by Type (2017-2028)

8.1.2 Asia Pacific Neurofibromatosis Type 1 Revenue by Type (2017-2028)

8.2 Asia Pacific Neurofibromatosis Type 1 Market Size by Application

8.2.1 Asia Pacific Neurofibromatosis Type 1 Sales by Application (2017-2028)

8.2.2 Asia Pacific Neurofibromatosis Type 1 Revenue by Application (2017-2028)

8.3 Asia Pacific Neurofibromatosis Type 1 Market Size by Region

8.3.1 Asia Pacific Neurofibromatosis Type 1 Sales by Region (2017-2028)

8.3.2 Asia Pacific Neurofibromatosis Type 1 Revenue by Region (2017-2028)

8.3.3 China

8.3.4 Japan

8.3.5 South Korea

8.3.6 India

8.3.7 Australia

8.3.8 Taiwan

8.3.9 Indonesia

8.3.10 Thailand

8.3.11 Malaysia

8.3.12 Philippines

9 Latin America

9.1 Latin America Neurofibromatosis Type 1 Market Size by Type

9.1.1 Latin America Neurofibromatosis Type 1 Sales by Type (2017-2028)

9.1.2 Latin America Neurofibromatosis Type 1 Revenue by Type (2017-2028)

9.2 Latin America Neurofibromatosis Type 1 Market Size by Application

9.2.1 Latin America Neurofibromatosis Type 1 Sales by Application (2017-2028)

9.2.2 Latin America Neurofibromatosis Type 1 Revenue by Application (2017-2028)

9.3 Latin America Neurofibromatosis Type 1 Market Size by Country

9.3.1 Latin America Neurofibromatosis Type 1 Sales by Country (2017-2028)

9.3.2 Latin America Neurofibromatosis Type 1 Revenue by Country (2017-2028)

9.3.3 Mexico

9.3.4 Brazil

9.3.5 Argentina

10 Middle East and Africa

10.1 Middle East and Africa Neurofibromatosis Type 1 Market Size by Type

10.1.1 Middle East and Africa Neurofibromatosis Type 1 Sales by Type (2017-2028)

10.1.2 Middle East and Africa Neurofibromatosis Type 1 Revenue by Type (2017-2028)

10.2 Middle East and Africa Neurofibromatosis Type 1 Market Size by Application

10.2.1 Middle East and Africa Neurofibromatosis Type 1 Sales by Application (2017-2028)

10.2.2 Middle East and Africa Neurofibromatosis Type 1 Revenue by Application (2017-2028)

10.3 Middle East and Africa Neurofibromatosis Type 1 Market Size by Country

10.3.1 Middle East and Africa Neurofibromatosis Type 1 Sales by Country (2017-2028)

10.3.2 Middle East and Africa Neurofibromatosis Type 1 Revenue by Country (2017-2028)

10.3.3 Turkey

10.3.4 Saudi Arabia

11 Company Profiles

11.1 AstraZeneca

11.1.1 AstraZeneca Corporation Information

11.1.2 AstraZeneca Overview

11.1.3 AstraZeneca Neurofibromatosis Type 1 Sales, Price, Revenue and Gross Margin (2017-2022)

11.1.4 AstraZeneca Neurofibromatosis Type 1 Product Model Numbers, Pictures, Descriptions and Specifications

11.1.5 AstraZeneca Recent Developments

11.2 Merck

11.2.1 Merck Corporation Information

11.2.2 Merck Overview

11.2.3 Merck Neurofibromatosis Type 1 Sales, Price, Revenue and Gross Margin (2017-2022)

11.2.4 Merck Neurofibromatosis Type 1 Product Model Numbers, Pictures, Descriptions and Specifications

11.2.5 Merck Recent Developments

12 Industry Chain and Sales Channels Analysis

12.1 Neurofibromatosis Type 1 Industry Chain Analysis

12.2 Neurofibromatosis Type 1 Key Raw Materials

12.2.1 Key Raw Materials

12.2.2 Raw Materials Key Suppliers

12.3 Neurofibromatosis Type 1 Production Mode & Process

12.4 Neurofibromatosis Type 1 Sales and Marketing

12.4.1 Neurofibromatosis Type 1 Sales Channels

12.4.2 Neurofibromatosis Type 1 Distributors

12.5 Neurofibromatosis Type 1 Customers

13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis

13.1 Neurofibromatosis Type 1 Industry Trends

13.2 Neurofibromatosis Type 1 Market Drivers

13.3 Neurofibromatosis Type 1 Market Challenges

13.4 Neurofibromatosis Type 1 Market Restraints

14 Key Findings in The Global Neurofibromatosis Type 1 Study

15 Appendix

15.1 Research Methodology

15.1.1 Methodology/Research Approach

15.1.2 Data Source

15.2 Author Details

15.3 Disclaimer

FEATURED COMPANIES

Astrazeneca plc

Merck

List of Tables

Table 1. Global Neurofibromatosis Type 1 Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)

Table 2. Major Manufacturers of 10 mg

Table 3. Major Manufacturers of 25 mg

Table 4. Global Neurofibromatosis Type 1 Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)

Table 5. Global Neurofibromatosis Type 1 Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)

Table 6. Global Neurofibromatosis Type 1 Sales by Region (2017-2022) & (K Units)

Table 7. Global Neurofibromatosis Type 1 Sales Market Share by Region (2017-2022)

Table 8. Global Neurofibromatosis Type 1 Sales by Region (2023-2028) & (K Units)

Table 9. Global Neurofibromatosis Type 1 Sales Market Share by Region (2023-2028)

Table 10. Global Neurofibromatosis Type 1 Revenue by Region (2017-2022) & (US$ Million)

Table 11. Global Neurofibromatosis Type 1 Revenue Market Share by Region (2017-2022)

Table 12. Global Neurofibromatosis Type 1 Revenue by Region (2023-2028) & (US$ Million)

Table 13. Global Neurofibromatosis Type 1 Revenue Market Share by Region (2023-2028)

Table 14. Global Neurofibromatosis Type 1 Sales by Manufacturers (2017-2022) & (K Units)

Table 15. Global Neurofibromatosis Type 1 Sales Share by Manufacturers (2017-2022)

Table 16. Global Neurofibromatosis Type 1 Revenue by Manufacturers (2017-2022) & (US$ Million)

Table 17. Global Neurofibromatosis Type 1 Revenue Share by Manufacturers (2017-2022)

Table 18. Neurofibromatosis Type 1 Price by Manufacturers (2017-2022) &(US$/Unit)

Table 19. Global Neurofibromatosis Type 1 Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 20. Global Neurofibromatosis Type 1 by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurofibromatosis Type 1 as of 2021)

Table 21. Neurofibromatosis Type 1 Manufacturing Base Distribution and Headquarters

Table 22. Manufacturers Neurofibromatosis Type 1 Product Offered

Table 23. Date of Manufacturers Enter into Neurofibromatosis Type 1 Market

Table 24. Mergers & Acquisitions, Expansion Plans

Table 25. Global Neurofibromatosis Type 1 Sales by Type (2017-2022) & (K Units)

Table 26. Global Neurofibromatosis Type 1 Sales by Type (2023-2028) & (K Units)

Table 27. Global Neurofibromatosis Type 1 Sales Share by Type (2017-2022)

Table 28. Global Neurofibromatosis Type 1 Sales Share by Type (2023-2028)

Table 29. Global Neurofibromatosis Type 1 Revenue by Type (2017-2022) & (US$ Million)

Table 30. Global Neurofibromatosis Type 1 Revenue by Type (2023-2028) & (US$ Million)

Table 31. Global Neurofibromatosis Type 1 Revenue Share by Type (2017-2022)

Table 32. Global Neurofibromatosis Type 1 Revenue Share by Type (2023-2028)

Table 33. Neurofibromatosis Type 1 Price by Type (2017-2022) & (US$/Unit)

Table 34. Global Neurofibromatosis Type 1 Price Forecast by Type (2023-2028) & (US$/Unit)

Table 35. Global Neurofibromatosis Type 1 Sales by Application (2017-2022) & (K Units)

Table 36. Global Neurofibromatosis Type 1 Sales by Application (2023-2028) & (K Units)

Table 37. Global Neurofibromatosis Type 1 Sales Share by Application (2017-2022)

Table 38. Global Neurofibromatosis Type 1 Sales Share by Application (2023-2028)

Table 39. Global Neurofibromatosis Type 1 Revenue by Application (2017-2022) & (US$ Million)

Table 40. Global Neurofibromatosis Type 1 Revenue by Application (2023-2028) & (US$ Million)

Table 41. Global Neurofibromatosis Type 1 Revenue Share by Application (2017-2022)

Table 42. Global Neurofibromatosis Type 1 Revenue Share by Application (2023-2028)

Table 43. Neurofibromatosis Type 1 Price by Application (2017-2022) & (US$/Unit)

Table 44. Global Neurofibromatosis Type 1 Price Forecast by Application (2023-2028) & (US$/Unit)

Table 45. North America Neurofibromatosis Type 1 Sales by Type (2017-2022) & (K Units)

Table 46. North America Neurofibromatosis Type 1 Sales by Type (2023-2028) & (K Units)

Table 47. North America Neurofibromatosis Type 1 Revenue by Type (2017-2022) & (US$ Million)

Table 48. North America Neurofibromatosis Type 1 Revenue by Type (2023-2028) & (US$ Million)

Table 49. North America Neurofibromatosis Type 1 Sales by Application (2017-2022) & (K Units)

Table 50. North America Neurofibromatosis Type 1 Sales by Application (2023-2028) & (K Units)

Table 51. North America Neurofibromatosis Type 1 Revenue by Application (2017-2022) & (US$ Million)

Table 52. North America Neurofibromatosis Type 1 Revenue by Application (2023-2028) & (US$ Million)

Table 53. North America Neurofibromatosis Type 1 Sales by Country (2017-2022) & (K Units)

Table 54. North America Neurofibromatosis Type 1 Sales by Country (2023-2028) & (K Units)

Table 55. North America Neurofibromatosis Type 1 Revenue by Country (2017-2022) & (US$ Million)

Table 56. North America Neurofibromatosis Type 1 Revenue by Country (2023-2028) & (US$ Million)

Table 57. Europe Neurofibromatosis Type 1 Sales by Type (2017-2022) & (K Units)

Table 58. Europe Neurofibromatosis Type 1 Sales by Type (2023-2028) & (K Units)

Table 59. Europe Neurofibromatosis Type 1 Revenue by Type (2017-2022) & (US$ Million)

Table 60. Europe Neurofibromatosis Type 1 Revenue by Type (2023-2028) & (US$ Million)

Table 61. Europe Neurofibromatosis Type 1 Sales by Application (2017-2022) & (K Units)

Table 62. Europe Neurofibromatosis Type 1 Sales by Application (2023-2028) & (K Units)

Table 63. Europe Neurofibromatosis Type 1 Revenue by Application (2017-2022) & (US$ Million)

Table 64. Europe Neurofibromatosis Type 1 Revenue by Application (2023-2028) & (US$ Million)

Table 65. Europe Neurofibromatosis Type 1 Sales by Country (2017-2022) & (K Units)

Table 66. Europe Neurofibromatosis Type 1 Sales by Country (2023-2028) & (K Units)

Table 67. Europe Neurofibromatosis Type 1 Revenue by Country (2017-2022) & (US$ Million)

Table 68. Europe Neurofibromatosis Type 1 Revenue by Country (2023-2028) & (US$ Million)

Table 69. Asia Pacific Neurofibromatosis Type 1 Sales by Type (2017-2022) & (K Units)

Table 70. Asia Pacific Neurofibromatosis Type 1 Sales by Type (2023-2028) & (K Units)

Table 71. Asia Pacific Neurofibromatosis Type 1 Revenue by Type (2017-2022) & (US$ Million)

Table 72. Asia Pacific Neurofibromatosis Type 1 Revenue by Type (2023-2028) & (US$ Million)

Table 73. Asia Pacific Neurofibromatosis Type 1 Sales by Application (2017-2022) & (K Units)

Table 74. Asia Pacific Neurofibromatosis Type 1 Sales by Application (2023-2028) & (K Units)

Table 75. Asia Pacific Neurofibromatosis Type 1 Revenue by Application (2017-2022) & (US$ Million)

Table 76. Asia Pacific Neurofibromatosis Type 1 Revenue by Application (2023-2028) & (US$ Million)

Table 77. Asia Pacific Neurofibromatosis Type 1 Sales by Region (2017-2022) & (K Units)

Table 78. Asia Pacific Neurofibromatosis Type 1 Sales by Region (2023-2028) & (K Units)

Table 79. Asia Pacific Neurofibromatosis Type 1 Revenue by Region (2017-2022) & (US$ Million)

Table 80. Asia Pacific Neurofibromatosis Type 1 Revenue by Region (2023-2028) & (US$ Million)

Table 81. Latin America Neurofibromatosis Type 1 Sales by Type (2017-2022) & (K Units)

Table 82. Latin America Neurofibromatosis Type 1 Sales by Type (2023-2028) & (K Units)

Table 83. Latin America Neurofibromatosis Type 1 Revenue by Type (2017-2022) & (US$ Million)

Table 84. Latin America Neurofibromatosis Type 1 Revenue by Type (2023-2028) & (US$ Million)

Table 85. Latin America Neurofibromatosis Type 1 Sales by Application (2017-2022) & (K Units)

Table 86. Latin America Neurofibromatosis Type 1 Sales by Application (2023-2028) & (K Units)

Table 87. Latin America Neurofibromatosis Type 1 Revenue by Application (2017-2022) & (US$ Million)

Table 88. Latin America Neurofibromatosis Type 1 Revenue by Application (2023-2028) & (US$ Million)

Table 89. Latin America Neurofibromatosis Type 1 Sales by Country (2017-2022) & (K Units)

Table 90. Latin America Neurofibromatosis Type 1 Sales by Country (2023-2028) & (K Units)

Table 91. Latin America Neurofibromatosis Type 1 Revenue by Country (2017-2022) & (US$ Million)

Table 92. Latin America Neurofibromatosis Type 1 Revenue by Country (2023-2028) & (US$ Million)

Table 93. Middle East and Africa Neurofibromatosis Type 1 Sales by Type (2017-2022) & (K Units)

Table 94. Middle East and Africa Neurofibromatosis Type 1 Sales by Type (2023-2028) & (K Units)

Table 95. Middle East and Africa Neurofibromatosis Type 1 Revenue by Type (2017-2022) & (US$ Million)

Table 96. Middle East and Africa Neurofibromatosis Type 1 Revenue by Type (2023-2028) & (US$ Million)

Table 97. Middle East and Africa Neurofibromatosis Type 1 Sales by Application (2017-2022) & (K Units)

Table 98. Middle East and Africa Neurofibromatosis Type 1 Sales by Application (2023-2028) & (K Units)

Table 99. Middle East and Africa Neurofibromatosis Type 1 Revenue by Application (2017-2022) & (US$ Million)

Table 100. Middle East and Africa Neurofibromatosis Type 1 Revenue by Application (2023-2028) & (US$ Million)

Table 101. Middle East and Africa Neurofibromatosis Type 1 Sales by Country (2017-2022) & (K Units)

Table 102. Middle East and Africa Neurofibromatosis Type 1 Sales by Country (2023-2028) & (K Units)

Table 103. Middle East and Africa Neurofibromatosis Type 1 Revenue by Country (2017-2022) & (US$ Million)

Table 104. Middle East and Africa Neurofibromatosis Type 1 Revenue by Country (2023-2028) & (US$ Million)

Table 105. AstraZeneca Corporation Information

Table 106. AstraZeneca Description and Major Businesses

Table 107. AstraZeneca Neurofibromatosis Type 1 Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)

Table 108. AstraZeneca Neurofibromatosis Type 1 Product Model Numbers, Pictures, Descriptions and Specifications

Table 109. AstraZeneca Recent Developments

Table 110. Merck Corporation Information

Table 111. Merck Description and Major Businesses

Table 112. Merck Neurofibromatosis Type 1 Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)

Table 113. Merck Neurofibromatosis Type 1 Product Model Numbers, Pictures, Descriptions and Specifications

Table 114. Merck Recent Developments

Table 115. Key Raw Materials Lists

Table 116. Raw Materials Key Suppliers Lists

Table 117. Neurofibromatosis Type 1 Distributors List

Table 118. Neurofibromatosis Type 1 Customers List

Table 119. Neurofibromatosis Type 1 Market Trends

Table 120. Neurofibromatosis Type 1 Market Drivers

Table 121. Neurofibromatosis Type 1 Market Challenges

Table 122. Neurofibromatosis Type 1 Market Restraints

Table 123. Research Programs/Design for This Report

Table 124. Key Data Information from Secondary Sources

Table 125. Key Data Information from Primary Sources

List of Figures

Figure 1. Neurofibromatosis Type 1 Product Picture

Figure 3. Global Neurofibromatosis Type 1 Market Share by Type in 2021 & 2028

Figure 3. 10 mg Product Picture

Figure 4. 25 mg Product Picture

Figure 5. Global Neurofibromatosis Type 1 Market Share by Application in 2021 & 2028

Figure 6. Hospitals

Figure 7. Clinics

Figure 8. Others

Figure 9. Neurofibromatosis Type 1 Report Years Considered

Figure 10. Global Neurofibromatosis Type 1 Sales 2017-2028 (K Units)

Figure 11. Global Neurofibromatosis Type 1 Revenue, (US$ Million), 2017 VS 2021 VS 2028

Figure 12. Global Neurofibromatosis Type 1 Revenue 2017-2028 (US$ Million)

Figure 13. Global Neurofibromatosis Type 1 Revenue Market Share by Region in Percentage: 2021 Versus 2028

Figure 14. Global Neurofibromatosis Type 1 Sales Market Share by Region (2017-2022)

Figure 15. Global Neurofibromatosis Type 1 Sales Market Share by Region (2023-2028)

Figure 16. North America Neurofibromatosis Type 1 Sales YoY (2017-2028) & (K Units)

Figure 17. North America Neurofibromatosis Type 1 Revenue YoY (2017-2028) & (US$ Million)

Figure 18. Europe Neurofibromatosis Type 1 Sales YoY (2017-2028) & (K Units)

Figure 19. Europe Neurofibromatosis Type 1 Revenue YoY (2017-2028) & (US$ Million)

Figure 20. Asia-Pacific Neurofibromatosis Type 1 Sales YoY (2017-2028) & (K Units)

Figure 21. Asia-Pacific Neurofibromatosis Type 1 Revenue YoY (2017-2028) & (US$ Million)

Figure 22. Latin America Neurofibromatosis Type 1 Sales YoY (2017-2028) & (K Units)

Figure 23. Latin America Neurofibromatosis Type 1 Revenue YoY (2017-2028) & (US$ Million)

Figure 24. Middle East & Africa Neurofibromatosis Type 1 Sales YoY (2017-2028) & (K Units)

Figure 25. Middle East & Africa Neurofibromatosis Type 1 Revenue YoY (2017-2028) & (US$ Million)

Figure 26. The Neurofibromatosis Type 1 Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021

Figure 27. The Top 5 and 10 Largest Manufacturers of Neurofibromatosis Type 1 in the World: Market Share by Neurofibromatosis Type 1 Revenue in 2021

Figure 28. Global Neurofibromatosis Type 1 Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021

Figure 29. Global Neurofibromatosis Type 1 Sales Market Share by Type (2017-2028)

Figure 30. Global Neurofibromatosis Type 1 Revenue Market Share by Type (2017-2028)

Figure 31. Global Neurofibromatosis Type 1 Sales Market Share by Application (2017-2028)

Figure 32. Global Neurofibromatosis Type 1 Revenue Market Share by Application (2017-2028)

Figure 33. North America Neurofibromatosis Type 1 Sales Market Share by Type (2017-2028)

Figure 34. North America Neurofibromatosis Type 1 Revenue Market Share by Type (2017-2028)

Figure 35. North America Neurofibromatosis Type 1 Sales Market Share by Application (2017-2028)

Figure 36. North America Neurofibromatosis Type 1 Revenue Market Share by Application (2017-2028)

Figure 37. North America Neurofibromatosis Type 1 Sales Share by Country (2017-2028)

Figure 38. North America Neurofibromatosis Type 1 Revenue Share by Country (2017-2028)

Figure 39. U.S. Neurofibromatosis Type 1 Revenue (2017-2028) & (US$ Million)

Figure 40. Canada Neurofibromatosis Type 1 Revenue (2017-2028) & (US$ Million)

Figure 41. Europe Neurofibromatosis Type 1 Sales Market Share by Type (2017-2028)

Figure 42. Europe Neurofibromatosis Type 1 Revenue Market Share by Type (2017-2028)

Figure 43. Europe Neurofibromatosis Type 1 Sales Market Share by Application (2017-2028)

Figure 44. Europe Neurofibromatosis Type 1 Revenue Market Share by Application (2017-2028)

Figure 45. Europe Neurofibromatosis Type 1 Sales Share by Country (2017-2028)

Figure 46. Europe Neurofibromatosis Type 1 Revenue Share by Country (2017-2028)

Figure 47. Germany Neurofibromatosis Type 1 Revenue (2017-2028) & (US$ Million)

Figure 48. France Neurofibromatosis Type 1 Revenue (2017-2028) & (US$ Million)

Figure 49. U.K. Neurofibromatosis Type 1 Revenue (2017-2028) & (US$ Million)

Figure 50. Italy Neurofibromatosis Type 1 Revenue (2017-2028) & (US$ Million)

Figure 51. Russia Neurofibromatosis Type 1 Revenue (2017-2028) & (US$ Million)

Figure 52. Asia Pacific Neurofibromatosis Type 1 Sales Market Share by Type (2017-2028)

Figure 53. Asia Pacific Neurofibromatosis Type 1 Revenue Market Share by Type (2017-2028)

Figure 54. Asia Pacific Neurofibromatosis Type 1 Sales Market Share by Application (2017-2028)

Figure 55. Asia Pacific Neurofibromatosis Type 1 Revenue Market Share by Application (2017-2028)

Figure 56. Asia Pacific Neurofibromatosis Type 1 Sales Share by Region (2017-2028)

Figure 57. Asia Pacific Neurofibromatosis Type 1 Revenue Share by Region (2017-2028)

Figure 58. China Neurofibromatosis Type 1 Revenue (2017-2028) & (US$ Million)

Figure 59. Japan Neurofibromatosis Type 1 Revenue (2017-2028) & (US$ Million)

Figure 60. South Korea Neurofibromatosis Type 1 Revenue (2017-2028) & (US$ Million)

Figure 61. India Neurofibromatosis Type 1 Revenue (2017-2028) & (US$ Million)

Figure 62. Australia Neurofibromatosis Type 1 Revenue (2017-2028) & (US$ Million)

Figure 63. Taiwan Neurofibromatosis Type 1 Revenue (2017-2028) & (US$ Million)

Figure 64. Indonesia Neurofibromatosis Type 1 Revenue (2017-2028) & (US$ Million)

Figure 65. Thailand Neurofibromatosis Type 1 Revenue (2017-2028) & (US$ Million)

Figure 66. Malaysia Neurofibromatosis Type 1 Revenue (2017-2028) & (US$ Million)

Figure 67. Philippines Neurofibromatosis Type 1 Revenue (2017-2028) & (US$ Million)

Figure 68. Latin America Neurofibromatosis Type 1 Sales Market Share by Type (2017-2028)

Figure 69. Latin America Neurofibromatosis Type 1 Revenue Market Share by Type (2017-2028)

Figure 70. Latin America Neurofibromatosis Type 1 Sales Market Share by Application (2017-2028)

Figure 71. Latin America Neurofibromatosis Type 1 Revenue Market Share by Application (2017-2028)

Figure 72. Latin America Neurofibromatosis Type 1 Sales Share by Country (2017-2028)

Figure 73. Latin America Neurofibromatosis Type 1 Revenue Share by Country (2017-2028)

Figure 74. Mexico Neurofibromatosis Type 1 Revenue (2017-2028) & (US$ Million)

Figure 75. Brazil Neurofibromatosis Type 1 Revenue (2017-2028) & (US$ Million)

Figure 76. Argentina Neurofibromatosis Type 1 Revenue (2017-2028) & (US$ Million)

Figure 77. Middle East and Africa Neurofibromatosis Type 1 Sales Market Share by Type (2017-2028)

Figure 78. Middle East and Africa Neurofibromatosis Type 1 Revenue Market Share by Type (2017-2028)

Figure 79. Middle East and Africa Neurofibromatosis Type 1 Sales Market Share by Application (2017-2028)

Figure 80. Middle East and Africa Neurofibromatosis Type 1 Revenue Market Share by Application (2017-2028)

Figure 81. Middle East and Africa Neurofibromatosis Type 1 Sales Share by Country (2017-2028)

Figure 82. Middle East and Africa Neurofibromatosis Type 1 Revenue Share by Country (2017-2028)

Figure 83. Turkey Neurofibromatosis Type 1 Revenue (2017-2028) & (US$ Million)

Figure 84. Saudi Arabia Neurofibromatosis Type 1 Revenue (2017-2028) & (US$ Million)

Figure 85. UAE Neurofibromatosis Type 1 Revenue (2017-2028) & (US$ Million)

Figure 86. Neurofibromatosis Type 1 Value Chain

Figure 87. Neurofibromatosis Type 1 Production Process

Figure 88. Channels of Distribution

Figure 89. Distributors Profiles

Figure 90. Bottom-up and Top-down Approaches for This Report

Figure 91. Data Triangulation

Figure 92. Key Executives Interviewed

REPORTS VIEWED RECENTLY

Global Neurofibromatosis Type 1 Market Insights and Forecast to 2028

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$4900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (10% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Neurofibromatosis Type 1 Market Insights and Forecast to 2028

Published Date: January 2022

Report Code: QYRE-Auto-23X8187

Global Neurofibromatosis Type 1 Market Insights and Forecast to 2028

Code: QYRE-Auto-23X8187

Report

January 2022

76 Pages

QYResearch

Region: Global,

FEATURED COMPANIES

Segment by Type

Segment by Application

BY COMPANY

BY REGION

FEATURED COMPANIES

FEATURED COMPANIES

REPORTS VIEWED RECENTLY

SELECT A FORMAT

Single User

Electronic (PDF)

$4900

Multi User

Electronic (PDF)

$7350

Enterprise User

Electronic (PDF)

$9800

HAVE A QUERY?

OUR CUSTOMER

RELATED REPORTS

120 Pages

Type: Report

Code: QYRE-Auto-28R1610

Mon Mar 14 00:00:00 UTC 2022

Add to Cart

120 Pages

Type: Report

Code: QYRE-Auto-34H5635

Fri Mar 11 00:00:00 UTC 2022

Add to Cart

120 Pages

Type: Report

Code: QYRE-Auto-35Y5644

Fri Mar 11 00:00:00 UTC 2022

Add to Cart

120 Pages

Type: Report

Code: QYRE-Auto-19G5824

Fri Mar 11 00:00:00 UTC 2022

Add to Cart

Support Contacts

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

POLICIES

THE COMPANY

CUSTOMER SUPPORT

OUR PRODUCTS

POLICES

Copyright © 2018 Valuates.com. All Rights Reserved.

Sitemap - Privacy Policy - Terms & Conditions